Salvinorin A

1. 2026-10-02issueIssued info_card
2. 2026-10-02srcA Protecting-Group-Free Synthesis of (-)-Salvinorin A.
3. 2026-10-02srcSalvinorin A has antiinflammatory and antinociceptive effects in experimental models of colitis in mice mediated by KOR and CB1 receptors.
4. 2026-10-02srcKappa opioid mediation of cannabinoid effects of the potent hallucinogen, salvinorin A, in rodents.
5. 2026-10-02srcLack of effect of sublingual salvinorin A, a naturally occurring kappa opioid, in humans: a placebo-controlled trial.
6. 2026-10-02srcDose-related effects of salvinorin A in humans: dissociative, hallucinogenic, and memory effects.
7. 2026-10-02srcDose-related behavioral, subjective, endocrine, and psychophysiological effects of the kappa opioid agonist Salvinorin A in humans.
8. 2026-10-02srcSalvinorin A moderates postischemic brain injury by preserving endothelial mitochondrial function via AMPK/Mfn2 activation.
9. 2026-10-02srcFrom local to global-fifty years of research on Salvia divinorum.
10. 2026-10-02srcSalvinorin A ameliorates pilocarpine-induced seizures by regulating hippocampal microglia polarization.
11. 2026-10-02srcPharmacokinetics of the potent hallucinogen, salvinorin A in primates parallels the rapid onset and short duration of effects in humans.
12. 2026-10-02srcDiscovery of Novel, Selective, and Nonbasic Agonists for the Kappa-Opioid Receptor Determined by Salvinorin A-Based Virtual Screening.
13. 2026-10-02srcAcute Effects of Hallucinogens on Functional Connectivity: Psilocybin and Salvinorin-A.
14. 2026-10-02srcSignaling Properties of Structurally Diverse Kappa Opioid Receptor Ligands: Toward in Vitro Models of in Vivo Responses.
15. 2026-10-02srcInhibitory effect of salvinorin A, from Salvia divinorum, on ileitis-induced hypermotility: cross-talk between kappa-opioid and cannabinoid CB(1) receptors.
16. 2026-10-02srcImmediate and Persistent Effects of Salvinorin A on the Kappa Opioid Receptor in Rodents, Monitored In Vivo with PET.
17. 2026-10-02srcThe translational potential of salvinorin A: systematic review and meta-analysis of preclinical studies.
18. 2026-10-02srcLigand and G-protein selectivity in the κ-opioid receptor.
19. 2026-10-02srcThe Acute Effects of the Atypical Dissociative Hallucinogen Salvinorin A on Functional Connectivity in the Human Brain.
20. 2026-10-02srcSalvinorin, a new trans-neoclerodane diterpene from Salvia divinorum (Labiatae)
21. 2026-10-02srcSalvia divinorum and Salvinorin A: An Update on Pharmacology and Analytical Methodology
22. 2026-10-02srcThe Association of Salvia divinorum and Psychotic Disorders: A Review of the Literature and Case Series.
23. 2026-10-02srcQuite a Profoundly Strange Experience: An Analysis of the Experiences of Salvia divinorum Users.
24. 2026-10-02srcSalvinorin-A Induces Intense Dissociative Effects, Blocking External Sensory Perception and Modulating Interoception and Sense of Body Ownership in Humans.
25. 2026-10-02srcNaltrexone but Not Ketanserin Antagonizes the Subjective, Cardiovascular, and Neuroendocrine Effects of Salvinorin-A in Humans.
26. 2026-10-02srcSalvinorin A inhibits colonic transit and neurogenic ion transport in mice by activating kappa-opioid and cannabinoid receptors.
27. 2026-10-02srcPotential anxiolytic- and antidepressant-like effects of salvinorin A, the main active ingredient of Salvia divinorum, in rodents.
28. 2026-10-02srcTime course of pharmacokinetic and hormonal effects of inhaled high-dose salvinorin A in humans.
29. 2026-10-02srcIntranasal salvinorin A improves neurological outcome in rhesus monkey ischemic stroke model using autologous blood clot.
30. 2026-10-02srcUse of Salvia divinorum in a nationally representative sample.
31. 2026-10-02srcOpioid Receptors in Psychedelia: Indirect Serotonergic Modulation of Direct KOR Activation by Salvinorin A.
32. 2026-10-02srcSolving an Old Puzzle: Elucidation and Evaluation of the Binding Mode of Salvinorin A at the Kappa Opioid Receptor.
33. 2026-10-02srcPharmacokinetics and Pharmacodynamics of Salvinorin A and Salvia divinorum: Clinical and Forensic Aspects
34. 2026-10-02srcSalvinorin A: a potent naturally occurring nonnitrogenous kappa opioid selective agonist.
35. 2026-10-02srcSalvinorin A, an active component of the hallucinogenic sage salvia divinorum is a highly efficacious kappa-opioid receptor agonist: structural and functional considerations.
36. 2026-10-02srcPharmacokinetics of the plant-derived kappa-opioid hallucinogen salvinorin A in nonhuman primates.
37. 2026-10-02srcN-methylacetamide analog of salvinorin A: a highly potent and selective kappa-opioid receptor agonist with oral efficacy.
38. 2026-10-02srcToxic psychosis after intake of the hallucinogen salvinorin A.
39. 2026-10-02srcSalvia divinorum: a psychopharmacological riddle and a mind-body prospect.
40. 2026-10-02srcSalvinorin A: A Mini Review of Physical and Chemical Properties Affecting Its Translation from Research to Clinical Applications in Humans.
41. 2026-10-02srcCytotoxic Effects of Salvinorin A, A Major Constituent of Salvia divinorum.
42. 2026-10-02srcErowid Salvia Divinorum Vault: Legal Status
43. 2026-10-02publicationPublication — publishagent-psx
44. 2026-10-02revisionr1.a1
45. 2026-10-02rulingRuling — psx:substance/salvinorin-a/proposal/article_section_proposals/488e5b61-8d5c-4eb5-84ac-8772920cc0bcfounder
46. 2026-10-02rulingRuling — psx:substance/salvinorin-a/proposal/article_section_proposals/b592b634-a27c-4c0f-a354-1aaa7e7737a5founder
47. 2026-09-04issueIssued emergency
48. 2026-09-04issueIssued info_card
49. 2026-09-04issueIssued notice
50. 2026-06-04proposal27 value proposals approved togetherone review action inferred from a shared reviewer and instant — the graph records one activity per proposal
51. 2026-06-04publicationPublication — backfill
52. 2026-05-07revisionRevision 1
53. 2026-05-07genGeneration — pipeline-v5 · with 3 morepipeline-v5
54. 2026-05-07rungeneration run

The same entries, as forms: six forms.